Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08046054 versus docetaxel in previously treated PD-L1-positive NSCLC
NL-OMON59692Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SGN-PDL1V in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started Feb 2026; status: recruiting.
02
Drugs
SGN-PDL1V
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59692.